Pulsatile farnesoid X receptor activation rewires liver disease pharmacology.

Nuclear receptor agonists face a dilemma: sustained receptor activation improves efficacy but inevitably exacerbates mechanism-based toxicity. Zang et al. challenge this by demonstrating that transient, physiologically synchronized farnesoid X receptor activation maintains efficacy while minimizing adverse effects, introducing temporal control of signaling as a new precision-therapeutic paradigm.